Tag: UK Health Security Agency

Monkeypox: continuing transmission in interconnected sexual networks

Latest UKHSA data shows monkeypox transmission continuing primarily in interconnected sexual networks of gay, bisexual and men who have sex with men (GBMSM).

The latest UK Health Security Agency (UKHSA) technical briefing on the current UK monkeypox outbreak shows no signs of a decline in the outbreak. In line with global observations, there is no evidence of sustained transmission beyond these networks.

The outbreak continues to grow and information from cases strongly suggests the virus is passing primarily via close or sexual contact. UKHSA Health Protection teams in all regions of England continue to identify and risk assess close contacts of confirmed cases.

The majority of people with monkeypox can be safely managed at home and there have been no deaths in the UK. Most people experience mild disease but it can cause a significant illness in some that requires hospitalisation, including severe pain.

A vaccination programme is beginning, and sexual health services will offer the vaccine to anyone considered to be at higher risk of exposure. This includes people with a recent history of multiple partners, participating in group sex, attending sex on premises venues, or have recently had a bacterial sexually transmitted infection.

Up to 6 July 2022, there were 1,517 laboratory confirmed cases in the UK. The median age of confirmed cases in the UK was 36 years old. In England, 99% of cases are male and 74% are known to be London residents. 16% (226) of England cases reported recent foreign travel, with 176 of these reporting travel within Europe.

The briefing includes a breakdown of events that cases reported attending, 572 in total. 17% of those who provided information had been to a sex-on-premises venue and while this does not confirm transmission occurred there, UKHSA continues to conduct outreach work with event organisers and to provide guidance on how to minimise risk across a range of settings.

Dr Meera Chand, Director of Clinical and Emerging Infections, UKHSA said: “It’s concerning that we are continuing to see the outbreak grow and we urge the public to do all they can to help us slow the spread.

“If you’ve recently had new or multiple sexual partners, please be vigilant to the symptoms of monkeypox, and be aware that many of the cases we’re seeing are finding only a single, or few, lesions.

“If you are concerned that you may have monkeypox, take a break from events, meeting with friends or having sexual contact. Instead, stay at home and contact 111 or your local sexual health service for advice. Please contact the clinic ahead of your visit and avoid close contact with others until you’ve been reviewed by a clinician.

“To assist with our contact tracing, we encourage everyone to ensure they exchange contact details with sexual partners.

“If you are called forward for vaccination, we strongly recommend that you take it.”

UKHSA will continue to publish regular technical briefings as the response to the outbreak continues.

Latest UK case numbers are available on GOV.UK.

UKHSA published the latest epidemiological overview for the ongoing monkeypox outbreak yesterday.

It shows that as of 7 July, there were 1,552 confirmed cases in the UK. Of these, 1,482 are in England with a significant majority of cases in London.

Latest UKHSA data shows monkeypox transmission continuing primarily in interconnected sexual networks of gay, bisexual and men who have sex with men (GBMSM).

Further epidemiological data and additional analysis can be found in UKHSA’s regular monkeypox technical briefings.

COVID-19 variants: latest updates

Latest updates on SARS-CoV-2 variants detected in the UK

The UK Health Security Agency (UKHSA) is reminding people to ensure their COVID-19 vaccinations are up to date and to continue following COVID-safe behaviours, as latest technical data indicates BA.4 and BA.5 have become dominant in the UK and are driving the recent increase in infections.

The UKHSA’s COVID-19 variant technical briefing 43, published today, includes epidemiological analysis that shows that Omicron BA.4 and BA.5 now make up more than half of new COVID-19 cases in England, accounting for approximately 22% and 39% of cases, respectively.

Omicron BA.4 and Omicron BA.5 were designated as variants of concern on 18 May on the basis of an apparent growth advantage over the previously-dominant Omicron BA.2 variant.

UKHSA’s latest analysis suggests that Omicron BA.5 is growing 35.1% faster than Omicron BA.2, while Omicron BA.4 is growing approximately 19.1% faster. This suggests that BA.5 is likely to become the dominant COVID-19 variant in the UK.

The increasing prevalence of Omicron BA.4 and BA.5 is likely to be a factor in the recent increase in cases seen in the UK and elsewhere, though there is currently no evidence that Omicron BA.4 and BA.5 cause more severe illness than previous variants.

So far, vaccination means that the rise in cases is not translating to a rise in severe illness and deaths. UKHSA scientists are urging anyone who has not had all the vaccines they are eligible for to make sure that they get them as soon as possible.

COVID-19 HAS NOT GONE AWAY, so it is also vitally important that people continue to follow the guidance. Stay at home if you have any respiratory symptoms or a fever and limit contact with others until you are feeling better, particularly if they are likely to be at greater risk if they contract COVID-19.

Professor Susan Hopkins, Chief Medical Advisor at UKHSA said: “It is clear that the increasing prevalence of Omicron BA.4 and BA.5 are significantly increasing the case numbers we have observed in recent weeks. We have seen a rise in hospital admissions in line with community infections but vaccinations are continuing to keep ICU admissions and deaths at low levels.

“As prevalence increases, it’s more important than ever that we all remain alert, take precautions, and ensure that we’re up to date with COVID-19 vaccinations, which remain our best form of defence against the virus. It’s not too late to catch up if you’ve missed boosters, or even first doses so please take your recommended vaccines.

“Our data also show that 17.5 per cent of people aged 75 years and over have not had a vaccine within the past six months, putting them more at risk of severe disease. We 2urge these people in particular to get up-to-date.

“If you have any symptoms of a respiratory infection, and a high temperature or feel unwell, try to stay at home or away from others – especially those who are elderly or vulnerable. Face coverings in crowded indoor spaces and hand washing will help to reduce transmission of infection and are especially important if you have any respiratory symptoms.”

UKHSA encourage everyone to continue to follow the most up-to date guidance.

As we learn to live safely with COVID-19, there are actions we can all take to help reduce the risk of catching COVID-19 and passing it on to others.

The risk of catching or passing on COVID-19 is greatest when someone who is infected is physically close to, or sharing an enclosed or poorly ventilated space with, other people.

You will not always know whether someone you come into contact with is at higher risk of becoming seriously ill from respiratory infections, including COVID-19. They could be strangers (for example people you sit next to on public transport) or people you may have regular contact with (for example friends and work colleagues).

There are simple things you can do in your daily life that will help reduce the spread of COVID-19 and other respiratory infections and protect those at highest risk.

Things you can choose to do are:

  • Get vaccinated
  • Let fresh air in if meeting others indoors
  • Practise good hygiene:
  • wash your hands
  • cover your coughs and sneezes
  • clean your surroundings frequently
  • Wear a face covering or a face mask, particularly if you are in crowded and enclosed spaces.

Scotland saw the largest increase in Covid cases in the UK last week, according to the Office for National Statistics (ONS).

It estimates about 250,700 people – one in 20 – had the virus in the week ending 17 June – an increase on the previous week when about 176,900, or one in 30 people, had Covid.

Meanwhile, NHS Lothian said a fifth of its nursing staff were off work as a result of the virus. With a 50% rise in hospital inpatients testing positive in the last week, NHS Lothian says its services are coming under increasing pressure.

Monkeypox vaccine to be offered more widely to help control outbreak

UK Health Security Agency publishes new guidance on offering the Imvanex vaccine to men considered to be at higher risk of exposure.

A strategy published today by the UK Health Security Agency (UKHSA) recommends that some gay and bisexual men at higher risk of exposure to monkeypox should be offered vaccines to help control the recent outbreak of the virus.

Although anyone can contract monkeypox, data from the latest outbreak shows higher levels of transmission within – but not exclusive to – the sexual networks of gay, bisexual and other men who have sex with men.

The virus is not currently defined as a sexually transmitted infection, but it can be passed on by close and intimate contact that occurs during sex.

In response, the UK Health Security Agency’s (UKHSA) vaccination strategy recommends offering the smallpox vaccine Imvanex, which is shown to be effective against monkeypox, to men considered to be at higher risk of exposure.

The strategy is endorsed by the Joint Committee on Vaccination and Immunisation (JCVI), which was consulted on the eligibility criteria for the vaccine.

An individual’s eligibility would depend on a number of factors but would be similar to the criteria used to assess those eligible for HIV pre-exposure prophylaxis (PrEP) – but applied regardless of HIV status.

The strategy states that a clinician may advise vaccination for someone who, for example, has multiple partners, participates in group sex or attends ‘sex on premises’ venues.

NHS England is due to set out details on how eligible people can get vaccinated shortly. People are advised not to come forward for the vaccine until contacted.

Dr Mary Ramsay, Head of Immunisation at UKHSA, said: “Our extensive contact tracing work has helped to limit the spread of the monkeypox virus, but we are continuing to see a notable proportion of cases in gay, bisexual and other men who have sex with men. By expanding the vaccine offer to those at higher risk, we hope to break chains of transmission and help contain the outbreak.

“Although most cases are mild, severe illness can occur in some people, so it is important we use the available vaccine to target groups where spread is ongoing. The NHS will soon set out details on how this will be delivered – so do not come forward for the vaccine yet.

“In the meantime, everyone should continue to be alert to any new spots, ulcers or blisters on any part of their body, particularly if they’ve had close contact with a new partner. If you think you have these symptoms, avoid close contact with others and call NHS 111 or your local sexual health centre, though please phone ahead before attending.”

Alex Sparrowhawk, Health Promotion Specialist at Terrence Higgins Trust, said: “This targeted vaccination programme is a positive move forward while the data still shows monkeypox is disproportionately affecting gay and bisexual men in the UK.

“We encourage everyone, regardless of their sexuality, to be vigilant about new spots, ulcers and blisters. We are continuing to closely monitor the latest data in order to play our part in providing the latest guidance and health information on monkeypox, to empower the communities most affected to best protect their health.”

Robbie de Santos, Director of Communications and External Affairs at Stonewall, said: “While we know anyone can catch monkeypox, we welcome the vaccine being offered to those gay and bi men who are eligible and currently at a higher risk of getting the virus.

“It is important that gay and bi men get the vaccine when offered to protect themselves and others. Let’s help get the outbreak under control so we can all have a safe and happy pride season.”

UKHSA is now publishing a regular data report on monkeypox in the UK. The report will be published every Tuesday and Friday.

Dr Sophia Makki, Incident Director at UKHSA, said: “We continue to see a steady increase in monkeypox cases. We’re reminding everyone to be aware of the symptoms of monkeypox, particularly if you’ve recently had new or multiple sexual partners, to help prevent further spread and protect others.

“If you have a rash with blisters, or any other monkeypox symptoms, don’t go to events, meet with friends or have sexual contact. Instead, stay at home and contact 111 or your local sexual health service for advice.

“Please contact the clinic ahead of your visit and avoid close contact with others until you’ve been reviewed by a clinician.”

Monkeypox: What we know so far

The UK Health Security Agency (UKHSA) has published its first technical briefing on the ongoing monkeypox outbreak. The briefing shares UKHSA analysis with other public health investigators and academic partners.

This first publication includes updated epidemiological data, with evidence from anonymised detailed interviews with patients which are helping us to understand transmission and to determine how to target interventions.

Of the cases interviewed, 81% were known to be London residents and 99% were male. The median age of confirmed cases in the UK was 38 years old.

152 cases participated in more detailed questionnaires. In this data, 151 of the 152 men interviewed identified as gay, bisexual, or men who have sex with men, or reported same sex contact. Recent foreign travel, within 21 days prior to symptom onset, was reported by 75 cases, with 59 of these reporting travel within Europe.

We also share preliminary assessment of the genomic differences between the outbreak virus and previous monkeypox viruses. In any emerging infection outbreak we assess the virus or bacteria for any changes. We will be working to investigate the significance of the mutations identified so far to determine if they will have any impact on the virus’ behaviour

Dr Meera Chand, Director of Clinical and Emerging Infections, UKHSA said: “We are working, both in the UK and together with global partners, to progress the investigations that we need to help us better understand the virus, its transmission and the best use of mitigations such as vaccines and treatments. We use the new data rapidly to inform the public health response and we continue to work to reduce transmission. 

“We are grateful to all those who have come forward for testing and the patients who continue to help us understand the outbreak through participating in studies and investigations.”

UKHSA has identified a number of aspects of this outbreak which require further investigation. We will release the results of our ongoing investigations in subsequent technical briefings – these will be published regularly.

Monkeypox: First case in Scotland

Monkeypox has been confirmed in an individual in Scotland. The individual is receiving care and treatment appropriate to their condition and contact tracing is underway.

Monkeypox is a viral infection usually found in West and Central Africa. The West African strain that has been recently detected in the UK is generally a mild self-limiting illness, spread by very close contact with someone already infected and with symptoms of monkeypox. Most people recover within a few weeks.

Public Health Scotland (PHS) is working with the UK Health Security Agency (UKHSA), Public Health Wales and Northern Ireland HSC Health Protection Agency to monitor and respond to potential and confirmed cases of monkeypox in the UK.

As of Friday 20 May, the UKHSA has identified 20 cases in England but more are expected.

Dr Nick Phin, Director of Public Health Science and Medical Director, PHS explains: “Public Health Scotland is aware of an individual in Scotland who is confirmed to have monkeypox. The affected individual is being managed and treated in line with nationally agreed protocols and guidance.

“We have well established and robust infection control procedures for dealing with such cases of infectious disease and these will be strictly followed.

“We are working with NHS Boards and wider partners in Scotland and the UK to investigate the source of this infection. Close contacts of the case are being identified and provided with health information and advice. This may include the offer of vaccination.

“The overall risk to the general public is low.

“Anyone with an unusual blister-like rash or small number of blister-like sores on any part of their body, including their genital area, should avoid close contact with others and seek medical advice if they have any concerns.”

Symptoms

Initial symptoms of monkey pox include fever or high temperature, headache, muscle aches, backache, swollen lymph nodes, chills and exhaustion.

A blister-like rash or small number of blister-like sores can develop, often beginning on the face, then spreading to other parts of the body, including the genital area.

The rash changes and goes through different stages, before finally forming a scab, which typically falls off over the course of a couple of weeks. Individuals are infectious from the point symptoms start until all the scabs fall off. During this time close contact with others must be avoided.

UKHSA identifies thirty-six more cases of monkeypox in England

The UK Health Security Agency (UKHSA) has detected 36 additional cases of monkeypox in England.

The latest cases bring the total number of monkeypox cases confirmed in England since 7 May to 56.

The virus does not usually spread easily between people, but it can be passed on through close person-to-person contact or contact with items used by a person who has monkeypox, such as clothes, bedding or utensils. Monkeypox is usually a self-limiting illness and most people recover within a few weeks.

While the current outbreak is significant and concerning, the risk to the UK population remains low.

Anyone with unusual rashes or lesions on any part of their body, especially their genitalia, should immediately contact NHS 111 or their local sexual health service.

A notable proportion of cases detected have been in gay and bisexual men, so UKHSA continues to urge this community to be alert to monkeypox symptoms.

People should notify clinics ahead of their visit and can be assured their call or discussion will be treated sensitively and confidentially.

Dr Susan Hopkins, Chief Medical Adviser, UKHSA, said: Alongside reports of further cases being identified in other countries globally, we continue to identify additional cases in the UK. Thank you to everyone who has come forward for testing already and supported our contact tracing efforts – you are helping us limit the spread of this infection in the UK.

“Because the virus spreads through close contact, we are urging everyone to be aware of any unusual rashes or lesions and to contact a sexual health service if they have any symptoms.

“A notable proportion of recent cases in the UK and Europe have been found in gay and bisexual men so we are particularly encouraging these men to be alert to the symptoms.”

UKHSA health protection teams are contacting people considered to be high-risk contacts of confirmed cases and are advising those who have been risk assessed and remain well to isolate at home for up to 21 days.

In addition, UKHSA has purchased supplies of a safe smallpox vaccine (called Imvanex) and this is being offered to identified close contacts of someone diagnosed with monkeypox to reduce the risk of symptomatic infection and severe illness.

We continue to engage with partners across the sector to ensure people are aware of the signs and symptoms and what action to take.

The vaccination of high-risk contacts of cases is underway. As of 10am on 23 May 2022, over 1,000 doses of Imvanex have been issued, or are in the process of being issued, to NHS Trusts. There remain over 3,500 doses of Imvanex in the UK.

COVID-19 variants identified in the UK

Omicron BA.4 and BA.5 designated as variant of concern by UKHSA

The UK Health Security Agency (UKHSA) has elevated the classification of the COVID-19 variants Omicron BA.4 and Omicron BA.5 to variants of concern (VOCs) on the basis of observed growth.

As of 17 May, 115 cases of BA.4 and 80 cases of BA.5 have been confirmed in England and the latest UKHSA variant technical briefing was published yesterday.

Whilst Omicron BA.4 and BA.5 are in the early stages of growth in the UK, analysis of the available data suggests that they are likely to have a growth advantage over the currently-dominant Omicron BA.2 variant.

There can be several reasons for growth advantage, but in the case of BA.4 and BA.5, laboratory data suggests a degree of immune escape which is likely to contribute.

Dr Meera Chand, Director of Clinical and Emerging Infections at UKHSA, “said: The reclassification of these variants as variants of concern reflects emerging evidence on the growth of BA.4 and BA.5 internationally and in the UK.

“Whilst the impact of these variants is uncertain, the variant classification system aims to identify potential risk as early as possible.

“UKHSA is undertaking further detailed studies. Data and analysis will be released in due course through our regular surveillance reporting.”

UK Covid Alert Level has moved from level 4 to level 3

“Based on advice from UKHSA, we the UK Chief Medical Officers and NHS England Medical Director have recommended to ministers that COVID Alert Level should move from level 4 to level 3.

“The current BA.2 driven Omicron wave is subsiding. Direct COVID-19 healthcare pressures continue to decrease in all nations and ONS community positivity estimates continue to decrease.

“We would like to thank healthcare staff for their remarkable efforts during a challenging time. Whilst it is reasonable to expect the number of cases to increase due to BA.4, BA.5 or BA2.12.1, it is unlikely in the immediate future to lead to significant direct COVID pressures. This will continue to be kept under review.”

Chief Medical Officer for England, Professor Chris Whitty

Chief Medical Officer for Northern Ireland, Dr Michael McBride

Chief Medical Officer for Scotland, Dr Gregor Smith

Chief Medical Officer for Wales, Dr Frank Atherton

NHS England National Medical Director, Professor Stephen Powis

FIRST MINISTER TESTS POSITIVE FOR COVID-19

First minister Nicola Sturgeon has tested positive for Covid

In a social media post last night, the first minister wrote: “Unfortunately I’ve tested positive for Covid this evening after experiencing mild symptoms.

“In line with Scottish government guidance, I’ll work from home over next few days, and hopefully be back out and about later next week.”

The First Minister attended a number of engagements in Washington DC this week and held a meeting with Sinn Fein’s Michelle O’Neill in Bute House yesterday.

Two more cases of monkeypox

The UK Health Security Agency (UKHSA) has detected 2 additional cases of monkeypox, one in London and one in the South East of England.

The latest cases bring the total number of monkeypox cases confirmed in England since 6 May to nine, with recent cases predominantly in gay, bisexual or men who have sex with men (MSM).

The 2 latest cases have no travel links to a country where monkeypox is endemic, so it is possible they acquired the infection through community transmission.

The virus spreads through close contact and UKHSA is advising individuals, particularly those who are gay, bisexual or MSM, to be alert to any unusual rashes or lesions on any part of their body, especially their genitalia, and to contact a sexual health service if they have concerns.

Monkeypox has not previously been described as a sexually transmitted infection, though it can be passed on by direct contact during sex. It can also be passed on through other close contact with a person who has monkeypox or contact with clothing or linens used by a person who has monkeypox.

The 2 new cases do not have known connections with previous confirmed cases announced on 16, 14 and 7 May.

UKHSA is working closely with the NHS and other stakeholders to urgently investigate where and how recent confirmed monkeypox cases were acquired, including how they may be linked to each other.

The virus does not usually spread easily between people. The risk to the UK population remains low.

Anyone with concerns that they could be infected with monkeypox is advised to contact NHS 111 or a sexual health clinic. People should notify clinics ahead of their visit. We can assure them their call or discussion will be treated sensitively and confidentially.

Monkeypox is a viral infection usually associated with travel to West Africa. It is usually a mild self-limiting illness, spread by very close contact with someone with monkeypox and most people recover within a few weeks.

Dr Susan Hopkins, Chief Medical Adviser, UKHSA, said: “These latest cases, together with reports of cases in countries across Europe, confirms our initial concerns that there could be spread of monkeypox within our communities.

“UKHSA has quickly identified cases so far and we continue to rapidly investigate the source of these infections and raise awareness among healthcare professionals.

“We are particularly urging men who are gay and bisexual to be aware of any unusual rashes or lesions and to contact a sexual health service without delay if they have concerns. Please contact clinics ahead of your visit.

“We are contacting any identified close contacts of the cases to provide health information and advice.

“Clinicians should be alert to individuals presenting with rashes without a clear alternative diagnosis and should contact specialist services for advice.”

Symptoms

Initial symptoms of monkeypox include fever, headache, muscle aches, backache, swollen lymph nodes, chills and exhaustion. A rash can develop, often beginning on the face, then spreading to other parts of the body including the genitals.

The rash changes and goes through different stages, and can look like chickenpox or syphilis, before finally forming a scab, which later falls off.

Increase in hepatitis cases in children under investigation

The UK Health Security Agency (UKHSA) has recently detected higher than usual rates of liver inflammation (hepatitis) in children. Similar cases are being assessed in Scotland.

Public health doctors and scientists at the UK’s public health agencies are continuing to investigate 74 cases of hepatitis (liver inflammation) in children since January 2022, where the usual viruses that cause infectious hepatitis (hepatitis A to E) have not been detected.

Of the confirmed cases, 49 are in England, 13 are in Scotland and the remainder are in Wales and Northern Ireland.

One of a number of potential causes under investigation is that a group of viruses called adenoviruses may be causing the illnesses. However, other possible causes are also being actively investigated, including coronavirus (COVID-19), other infections or environmental causes.

There is no link to the COVID-19 vaccine. None of the currently confirmed cases in the UK has been vaccinated.

Adenoviruses are a family of common viruses that usually cause a range of mild illnesses and most people recover without complications. They can cause a range of symptoms, including colds, vomiting and diarrhoea. While they don’t typically cause hepatitis, it is a known rare complication of the virus.

Adenoviruses are commonly passed from person to person and by touching contaminated surfaces, as well as through the respiratory route.

The most effective way to minimise the spread of adenoviruses is to practice good hand and respiratory hygiene and supervise thorough handwashing in younger children.

Dr Meera Chand, Director of Clinical and Emerging Infections at UKHSA, said: “We are working swiftly with the NHS and public health colleagues in Scotland, Wales and Northern Ireland to investigate a wide range of possible factors which may be causing children to be admitted to hospital with liver inflammation known as hepatitis.

“One of the possible causes that we are investigating is that this is linked to adenovirus infection. However, we are thoroughly investigating other potential causes.

“Normal hygiene measures such as good handwashing – including supervising children – and respiratory hygiene, help to reduce the spread of many of the infections that we are investigating.

“We are also calling on parents and guardians, to be alert to the signs of hepatitis – including jaundice – and to contact a healthcare professional if they are concerned.”

UKHSA, working with partners, will continue to make the public aware of findings throughout the course of the investigation.

Hepatitis symptoms include:

  • dark urine
  • pale, grey-coloured poo
  • itchy skin
  • yellowing of the eyes and skin (jaundice)
  • muscle and joint pain
  • a high temperature
  • feeling and being sick
  • feeling unusually tired all the time
  • loss of appetite
  • tummy pain

No need for second booster at this time, say health experts

Boosters continue to provide high levels of protection against severe disease from Omicron in older adults

Latest data from UKHSA shows booster doses are continuing to provide high levels of protection against severe disease from the Omicron variant among older adults.

Figures show that around 3 months after they received the third jab, protection against hospitalisation among those aged 65 and over remains at about 90%.

With just 2 vaccine doses, protection against severe disease drops to around 70% after 3 months and to 50% after 6 months.

The Joint Committee on Vaccination and Immunisation (JCVI) has taken this latest evidence into account in their ongoing review of the booster programme.

The Committee advises that at this present time:

  • there is no immediate need to introduce a second booster dose, or fourth jab, to the most vulnerable (care home residents and those aged over 80) – the timing and need for further booster doses will continue to be reviewed as the data evolves
  • priority should continue to be given to rolling out first booster doses to all age groups
  • unvaccinated individuals should come forward for their first 2 doses as soon as possible

Professor Wei Shen Lim, the JCVI’s chair of COVID-19 immunisation, said: “The current data shows the booster dose is continuing to provide high levels of protection against severe disease, even for the most vulnerable older age groups.

“For this reason, the committee has concluded there is no immediate need to introduce a second booster dose, though this will continue to be reviewed.

“The data is highly encouraging and emphasises the value of a booster jab. With Omicron continuing to spread widely, I encourage everyone to come forward for their booster dose, or if unvaccinated, for their first 2 doses, to increase their protection against serious illness.”

The latest study looked at booster doses in those aged over 65, who were among the first to be eligible when the booster rollout began in mid-September.

Whilst with a booster dose, the duration of protection against severe disease remains high, protection against mild symptomatic infection is more short-lived and drops to around 30% by about 3 months.

UK coronavirus alert level increased from Level 3 to Level 4

Following advice from the UK Health Security Agency and in the light of the rapid increase in Omicron cases, the UK Chief Medical Officers and NHS England National Medical Director have recommended to ministers that the UK COVID-19 alert level should increase from Level 3 to Level 4.

Transmission of COVID-19 is already high in the community, mainly still driven by Delta, but the emergence of Omicron adds additional and rapidly increasing risk to the public and healthcare services.

Early evidence shows that Omicron is spreading much faster than Delta and that vaccine protection against symptomatic disease from Omicron is reduced. Data on severity will become clearer over the coming weeks but hospitalisations from Omicron are already occurring and these are likely to increase rapidly.

When vaccine protection is reduced in the way that is happening with Omicron it is essential to top up that protection with a booster. Both booster vaccines (Pfizer and Moderna) increase the immune response substantially and show good effectiveness although with some reduction compared to Delta.

The NHS is currently under pressure mainly driven by non-COVID-19 pressures. With a variant spreading with increased transmissibility and reduced vaccine effectiveness, we are likely to see this pressure rise soon.

It is extremely important that if you are eligible, you get your COVID-19 vaccination now – whether this be your first, second or booster dose.

People should continue take sensible precautions including ventilating rooms, using face coverings, testing regularly and isolating when symptomatic.

Chief Medical Officer for England, Professor Chris Whitty

Chief Medical Officer for Northern Ireland, Professor Sir Michael McBride

Chief Medical Officer for Scotland, Professor Gregor Smith

Chief Medical Officer for Wales, Dr Frank Atherton

NHS England National Medical Director, Professor Stephen Powis